Vatanbir

Main Menu

  • Home
  • Transport business
  • Transport corporation
  • Transport industry
  • Tank transport
  • Transport lending

Vatanbir

Header Banner

Vatanbir

  • Home
  • Transport business
  • Transport corporation
  • Transport industry
  • Tank transport
  • Transport lending
Transport corporation
Home›Transport corporation›Balchem ​​Corporation Completes Acquisition of Kappa

Balchem ​​Corporation Completes Acquisition of Kappa

By Linda Glidden
June 21, 2022
0
0

NEW HAMPTON, NY, June 21, 2022 (GLOBE NEWSWIRE) — Balchem ​​Corporation (NASDAQ: BCPC), a global specialty ingredients company focused on nutrition and health, announced today that it has finalized its acquisition of Kappa Bioscience AS, a leading science company. manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway. The signing of a definitive agreement for the acquisition of Kappa Bioscience AS was previously announced on June 14, 2022.

With this acquisition, Balchem ​​is accelerating its strategy to expand its science-based specialty nutrient portfolio with leading positions in growing markets. Vitamin K2 is a fast-growing, specialty vitamin that plays a crucial role in the human body for bone health, heart health, immunity, and athletic performance. Primarily, vitamin K2 supports the transport and distribution of calcium in the body. Vitamin K2 is important at all stages of life, from pregnancy and early life to healthy aging. Kappa K2VITAL® Branded Vitamin K2 is the leading synthetic Vitamin K2 and is backed by strong intellectual property and an extensive clinical research portfolio.

About Balchem ​​Corporation
Balchem ​​Corporation develops, manufactures and markets specialty ingredients that enhance and enhance the health and well-being of life on the planet by providing cutting-edge solutions and the highest quality products for a range of industries in the whole world. The Company reports three business segments: Human Nutrition and Health; animal nutrition and health; and specialty products. The Human Nutrition & Health segment provides customized food and beverage ingredient systems and key nutrients in a variety of applications in the food, supplement and pharmaceutical industries. The Animal Nutrition and Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem ​​provides specialty packaged chemicals for use in healthcare and other industries, and also supplies chelated minerals to the agricultural micronutrient market.

About Kappa Bioscience
Kappa Bioscience AS was founded in Oslo, Norway in 2006 following a breakthrough discovery: the synthesis of pure and fully bioactive Vitamin K2 MK-7, an essential vitamin needed to direct calcium in our body and maintain heart, bones and many other healthy things. Today, this pioneering spirit is still going strong. With patented processes, innovative technology and recognized expertise, Kappa Bioscience AS produces K2VITAL® and K2VITAL® Delta; vitamin K2 with unparalleled purity and stability, in a wider range of formulations than anyone else, to bring the best possible vitamin K2 benefits to everyone.

From vitamin K2 and turnkey solutions to research and marketing initiatives, product launches and growth strategies, Kappa Bioscience AS believes in getting it right. It means developing products and services that set new standards of excellence, made with integrity and through close collaboration. In collaboration with its partners, Kappa Bioscience AS helps the health and nutrition industry to reach a milestone, without cutting corners.

Forward-looking statement
This release contains forward-looking statements, which reflect Balchem’s expectations or beliefs regarding future events that involve risks and uncertainties. Balchem ​​cannot guarantee that the expectations reflected in the forward-looking statements will prove to be accurate and a variety of factors could cause actual results to differ materially from Balchem’s expectations, including the risks and factors identified in Balchem’s annual report on Form 10-K for the year ended December 31. , 2021. Forward-looking statements are qualified in their entirety by the above cautionary statement. Balchem ​​undertakes no obligation to update its outlook or other forward-looking statements as of any future date.

Contact:

Jacqueline Yarmolowicz, Executive Assistant

Phone: 845-326-5600

Email: [email protected]

Related posts:

  1. Transportation Electronic Tickets (E) Market 2021 | Extensive growth | Opportunities
  2. Gujarat transfers 77 IAS officer in major reshuffle
  3. Tamil Nadu lifts restrictions on inter-district travel in four districts; MTC, subway services to re- The New Indian Express
  4. Road and Rail Intelligent Transportation Systems Market Size and Forecast to 2027

Archives

  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • January 2020
  • December 2019
  • November 2019

Recent Posts

  • Transport for London celebrates 50 years of Pride with its biggest ever poster exhibition
  • Hydrogen – Viritech introduces new hydrogen powertrain technology in Apricale hypercar
  • 2022-06-29 | NYSE:LLAP | Press release
  • DVIDS – News – 1041st Transportation Company invests miles in Dugway
  • Transportation Consulting Services Market 2022 Strategic Analysis, Growth Drivers, Industry Trends, Demand and Future Opportunities to 2031

Categories

  • Tank transport
  • Transport business
  • Transport corporation
  • Transport industry
  • Transport lending
  • Privacy Policy
  • Terms and Conditions